Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wichelhaus, T. A.
Right arrow Articles by Böddinghaus, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wichelhaus, T. A.
Right arrow Articles by Böddinghaus, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 153-156
© 2001 The British Society for Antimicrobial Chemotherapy

Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus

T. A. Wichelhaus,*, V. Schäfer, V. Brade and B. Böddinghaus

Institute of Medical Microbiology, University Hospital, Paul-Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany

The in vitro antibacterial activities of the rifamycin derivatives rifampicin and KRM-1648 against 150 Staphylococcus aureus isolates were determined. The MICs of rifampicin and KRM-1648 for 90% of rifampicin-susceptible S. aureus isolates (n = 100) were 0.016 and 0.001 mg/L, respectively. In rifampicin-resistant S. aureus isolates (n = 50), different levels of resistance to rifamycins were associated with mutations at different sites in rpoB. Mutations at some sites were associated with high-level resistance to both rifamycins, while certain mutations were associated with the activity of KRM-1648 being <= 100-fold better than that of rifampicin.

* Corresponding author. Tel: +49-69-6301-6438; Fax: +49-69-6301-5767; E-mail: wichelhaus{at}em.uni-frankfurt.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Besier, J. Zander, B. C. Kahl, P. Kraiczy, V. Brade, and T. A. Wichelhaus
The Thymidine-Dependent Small-Colony-Variant Phenotype Is Associated with Hypermutability and Antibiotic Resistance in Clinical Staphylococcus aureus Isolates
Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2183 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. M. Rothstein, R. S. Farquhar, K. Sirokman, K. L. Sondergaard, C. Hazlett, A. A. Doye, J. K. Gwathmey, S. Mullin, J. van Duzer, and C. K. Murphy
Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3658 - 3664.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. K. Murphy, S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein
In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 827 - 834.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Yu, J. Wu, K. P. Francis, T. F. Purchio, and J. L. Kadurugamuwa
Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model
J. Antimicrob. Chemother., April 1, 2005; 55(4): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. J. Suchland, A. Bourillon, E. Denamur, W. E. Stamm, and D. M. Rothstein
Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1120 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
W. Achour, O. Guenni, M. Fines, R. Leclercq, and A. Ben Hassen
rpoB Mutations in Streptococcus mitis Clinical Isolates Resistant to Rifampin
Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2757 - 2759.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Cruchaga, M. Perez-Vazquez, F. Roman, and J. Campos
Molecular basis of rifampicin resistance in Haemophilus influenzae
J. Antimicrob. Chemother., December 1, 2003; 52(6): 1011 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. M. Roblin, T. Reznik, A. Kutlin, and M. R. Hammerschlag
In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1135 - 1136.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.